Drug Type Monoclonal antibody |
Synonyms ICT 23, ICT-23 |
Target |
Mechanism BTN2A1 inhibitors(Butyrophilin subfamily 2 member A1 inhibitors), BTN2A2 inhibitors(Butyrophilin subfamily 2 member A2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | FR | Imcheck Therapeutics SASStartup | - |